A-S Gauchez
Overview
Explore the profile of A-S Gauchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fournier A, Mondillon L, Dantzer C, Gauchez A, Ducros V, Mathieu N, et al.
Neurogastroenterol Motil
. 2018 Jun;
30(10):e13387.
PMID: 29856118
Background: Negativity is often observed in patients with irritable bowel syndrome (IBS). No study has examined their emotional expressiveness as a marker of emotional reactivity. We investigated IBS patients' vulnerability...
2.
Jalbert M, Mignot A, Gauchez A, Dobrokhotov A, Fourcade J
Nephrol Ther
. 2018 May;
14(4):231-236.
PMID: 29709532
Introduction: Hypercalcemia is not a rare event and can lead to severe consequences. Its main etiologies are primary hyperparathyroidism and neoplasic conditions. The iatrogenic etiology by vitamin D intoxication is...
3.
Gauchez A, Lamy P, Descotes J
Prog Urol
. 2015 Oct;
25(16):1121-4.
PMID: 26475234
Introduction: With the widespread use of prostate specific antigen (PSA) prescription and despite the automatization of PSA assessment, clinicians should not forget the analytical interference of PSA immunoassays due to...
4.
Riedinger J, Mousseau M, Gauchez A
Ann Biol Clin (Paris)
. 2008 Jun;
66(3):333-40.
PMID: 18558573
The dynamic interpretation of the serum concentrations of markers is frequently used to calculate biological indicators of therapeutic efficiency and relapse. But analysis of marker kinetics can also help improve...
5.
Gauchez A, Pez E, Boutonnat J, Bourre J, Pelletier L, Payan R, et al.
Ann Biol Clin (Paris)
. 2007 Nov;
65(6):653-8.
PMID: 18039611
Fifteen per cent of metastatic breast cancer will develop symptomatic leptomeningeal metastases. The introduction of trastuzumab (Herceptin) therapy has improved the response rates of survival of patients with metastatic breast...